Published in Hepatitis Weekly, December 29th, 2003
Although efficacy is not a stated objective of the phase IB clinical trial and the number of patients was small, results showed that isatoribine is biologically active in adults with chronic hepatitis C virus (HCV) infection.
Isatoribine, which is believed to act by a mechanism of action involving interaction with Toll-like receptor 7 (TLR7) and stimulate the patient's own immune system, is one of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly